Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Drug Dev Ind Pharm ; 38(3): 259-63, 2012 Mar.
Article in English | MEDLINE | ID: mdl-21854223

ABSTRACT

Conventional treatment of tuberculosis (TB) demands a long course therapy (6 months), known to originate multiple drug resistant strains (MDR-TB), which emphasizes the urgent need for new antituberculous drugs. The purpose of this study was to investigate a novel treatment for TB meant to improve patient compliance by reducing drug dosage frequency. Polymeric microparticles containing the synthetic analogue of neolignan, 1-phenyl-2-phenoxiethanone (LS-2), were obtained by a method of emulsification and solvent evaporation and chemically characterized. Only representative LS-2-loaded microparticles were considered for further studies involving experimental murine TB induced by Mycobacterium tuberculosis H37Rv ATCC 27294. The LS-2-loaded microparticles were spherical in shape, had a smooth wall and showed an encapsulation efficiency of 93% in addition to displaying sustained release. Chemotherapeutic potential of LS-2 entrapped in microparticles was comparable to control groups. These findings are encouraging and indicate that LS-2-loaded microparticles are a potential alternative to conventional chemotherapy of TB.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Drug Carriers , Lignans/administration & dosage , Mycobacterium tuberculosis/drug effects , Tuberculosis, Pulmonary/drug therapy , Animals , Biocompatible Materials , Disease Models, Animal , Drug Resistance, Bacterial , Humans , Lactic Acid , Male , Mice , Mice, Inbred BALB C , Microspheres , Models, Animal , Particle Size , Patient Compliance , Polyglycolic Acid , Polylactic Acid-Polyglycolic Acid Copolymer , Time Factors
2.
J Nat Prod ; 67(3): 510-22, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15043447

ABSTRACT

Brazil is blessed with a great biodiversity, which constitutes one of the most important sources of biologically active compounds, even if it has been largely underexplored. As is the case of the Amazon and Atlantic rainforests, the Brazilian marine fauna remains practically unexplored in the search for new biologically active natural products. Considering that marine organisms have been shown to be one of the most promising sources of new bioactive compounds for the treatment of different human diseases, the 8000 km of the Brazilian coastline represents a great potential for finding new pharmacologically active secondary metabolites. This review presents the status of marine natural products chemistry in Brazil, including results reported by different research groups with emphasis on the isolation, structure elucidation, and evaluation of biological activities of natural products isolated from sponges, ascidians, octocorals, and Opistobranch mollusks. A brief overview of the first Brazilian program on the isolation of marine bacteria and fungi, directed toward the production of biologically active compounds, is also discussed. The current multidisciplinary collaborative program under development at the Universidade de São Paulo proposes to establish a new paradigm toward the management of the Brazilian marine biodiversity, integrating research on the species diversity, ecology, taxonomy, and biogeography of marine invertebrates and microorganisms. This program also includes a broad screening program of Brazilian marine bioresources, to search for active compounds that may be of interest for the development of new drug leads.


Subject(s)
Biological Products , Marine Biology , Pharmaceutical Preparations , Animals , Anthozoa/chemistry , Biological Products/chemistry , Biological Products/isolation & purification , Biological Products/pharmacology , Brazil , Molecular Structure , Mollusca/chemistry , Pharmaceutical Preparations/chemistry , Pharmaceutical Preparations/isolation & purification , Porifera/chemistry , Urochordata/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...